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To investigate the immune-rejection and tumor-
formation potentials of induced pluripotent stem cells
and other stem cells, we devised a model—designated
the “Mouse Clone Model”—which combined the theory
of somatic animal cloning, tetraploid complementation,
and induced pluripotent stem cells to demonstrate the
applicability of stem cells for transplantation therapy.The shortcoming of this research is to use the sameIn 2011, Zhao et al. [1] reported that, compared with
embryonic stem cells (ESCs), induced pluripotent stem
cells (iPSCs) showed more immune rejection and over-
expression of immunogenicity-related genes. This report
shed shadows on the great promise of iPSCs as the re-
newable sources of autologous cells for regenerative
medicine. Because of the different origins and treatment
of ESCs and iPSCs [2–4], it is reasonable that there are
some differences between them, even though iPSCs can
eventually give rise to viable mice by tetraploid comple-
mentation [5, 6] and iPSC mice can make further mice
[7]. These data demonstrate that iPSCs could have the
same pluripotency as ESCs. At present, iPSCs can be
generated with several different protocols, including
retroviral infection [3], lentiviral transduction [8], nonviral
minicircle vector transfection [9], and so forth. It is true
that a heterogeneic situation will always be found in iPSCs.
Polo et al. [10] reported that iPSCs derived from different
cell types, such as mouse fibroblasts, hematopoietic cells,
and myogenic cells, exhibited distinct transcriptional and
epigenetic patterns. Furthermore, the cellular origin influ-
ences the in vitro differentiation potentials of iPSCs. But* Correspondence: gang.zhang@utoronto.ca; yizhang.zhang@mail.utoronto.ca
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(http://creativecommons.org/publicdomain/zecontinuous passaging of iPSCs largely attenuates these dif-
ferences. These data indicate that the heterogeneity of
iPSCs might be decreased by further reprogramming with
more passaging [10]. Great achievements have so far been
made in the application of iPSC transplantation. For ex-
ample, the successful corrections of sickle cell anemia,
Fanconi anemia, and tyrosinemia [11–13] via the trans-
plantation of iPSC-derived differentiated cell types into
diseased mouse models.
strain of C57BL/6 (B6) mice as recipients to test the im-
mune rejection of the iPSCs, derived from mice which
are within the same strain but are not the same individ-
ual mice, between the donors of iPSCs and the recipients
[1]. For example, C57BL/6 mice are an inbred strain and
are nearly identical to each other in genotype due to
long inbreeding. Although transplantations between in-
bred mice have been conventionally used as a model to
test immune acceptance and are considered autologous
transplantation, and in some sense they are in theory
equivalent to autologous human tissue/cell transplanta-
tions, this is not completely true. Here, it is worthy of note
that inbred mice are nearly identical in genotype, but they
are not exactly the same. Furthermore, even though it is
well known that inbred mice can fully accept the same in-
bred strain mouse organs, including skin grafts, and there-
fore are a rigorous model to assess immune tolerance, this
might not be the same in the case of stem cell transplant-
ation therapy, such as iPSC and ESC transplantations. It is
well known that immune rejection exists not only species
specifically, but also individual specifically, including
within the same strain, due to alloimmunity [14].
To evaluate the applicability of iPSCs for autologous
transplantation, we devised a novel animal model by
combining the theory of animal cloning [15], the protocol
of tetraploid complementation [16], and the induction of
iPSCs [3, 4, 7] to establish a large number of cloned mice
derived from a single inner cell mass (ICM) of mousearticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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step include, first of all, that we can compare the similarity
and difference between ESCs and iPSCs of the same ori-
gin, because they are genetically from the same mouse
blastocyst. In addition, by using ESCs as the starting point,
we can produce both ESC mice and iPSC mice, so we can
compare them to determine whether they are exactly the
same or have some differences. Theoretically, these cloned
mice are exactly identical to each other. Therefore, truly
autologous stem cell transplantations can be performedFig. 1 Scheme of the “Mouse Clone Model” for stem cell transplantation. a
from a. c 2n ESCs separated from b for microinjection. d Many 2n mouse t
e Many 4n one-cell embryos fused from d. f Many 4n blastocysts generate
tetraploid complementation. g Mouse clone from 2n ESCs, theoretically all
from g, using these stem cells to transplant g mice; theoretically transpla
protocols [3, 4, 7]; theoretically, they should be the same as g, but for ep
iPSCs can be differentiated or directly transplanted into the mice of g. Th
on the data of immune rejection and tumor formation, using the “good”
immune rejection to generate iPSC mice. j First generation of iPSC mice gene
This step can identify the “good” iPSC lines which can generate live mice from
i, we can identify “good” iPSC lines, which can generate live mice, cannot form
tissue-specific stem cells isolated from first-generation iPSC mice. These iPSC m
transplanted into the ESC-derived mice and iPSC-derived mice to investigate
lines from first-generation iPSC mice. These lines are again investigated
tetraploid complementation to produce the second generation of iPSC mice.
iPSC mice, and isolate iPSCs and tissue-specific stem cells for transplantation. U
from a unique 2n mouse blastocyst, for the investigation of stem cell the
pluripotent stem cellbetween them. Moreover, because the starting point of the
cloned mice is the ESCs, the transplantation characteris-
tics among ESCs, iPSCs, and tissue-specific stem cells
can be analyzed with this model. Adopting this clone of
mice as a unique source, iPSC lines can be induced and
established. At the same time, other stem cells of different
tissues can also be isolated. As a result, the iPSCs and
tissue-specific stem cells, together with their progenies of
different differentiated stages, can be tested by transplant-
ing them into the mice of the same clone to achieve trulyOne unique 2n mouse blastocyst. b 2n ESCs isolated and cultured
wo-cell embryos from the same or different mouse strains with a.
d from e and injected with 2n ESCs from a to produce ESC mice by
the same as each other. h Various tissue-specific stem cells isolated
nted into “themselves”. i Many induced iPSCs from g with different
igenetic reasons there are some differences between them. These
is step could identify “good” iPSC lines from “bad” iPSC lines based
iPSC lines which do not form tumor and do not have, or have less,
rated from different iPSC lines from i by tetraploid complementation.
those which cannot. Combined with the data from the transplantation
tumor, and do not have, or have less, immune rejection. k Various
ice-derived tissue-specific stem cells can be differentiated or directly
their efficacies according to the commonly agreed criteria. l Induced iPSC
by transplanting into ESC mice, first-generation iPSC mice, and
m Keep on repeating to form a large group of different generations of
sing this model and strategy, a large clone of mice will be established
rapy. ESC Embryonic stem cell, ICM Inner cell mass, iPSC Induced
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specific iPSCs for the patients (Fig. 1). In addition,
during the reprogramming of iPSCs, some genetically
different cell lines with different pluripotency can be
generated by different protocols and other unknown
reasons [1, 3, 5–7]; therefore, this model can also help to
answer which lines are better for therapeutic applications
with less immune rejection. Furthermore, the availability of
plenty of the same-origin clone of mice can further allow
the investigators to examine the therapeutic advantages of
various kinds of tissue-specific stem cells with different
differentiated stages. The discovery that mice can be
serially recloned for up to 25 generations with consistent
cloning efficiency and without evident genomic errors in-
dicated that mice possibly can be recloned limitlessly by
the somatic nuclear transfer method [17]. Thus, in theory,
mice can also possibly be limitlessly recloned by tetraploid
complementation strategy with iPSCs. Hence, iPSCs can
be isolated and induced limitlessly from these iPSC mice.
Although autoimmune diseases exist, and in some cases
the transplantation tolerance observed in mouse models
cannot be validated in large animal models and human due
to different species, this strategy will at least theoretically
provide a clone of truly identical mice for stem cell therapy
investigation. Using this method, a clone of immortal mice
can be established eventually, and they will benefit the stem
cell therapy research greatly in a mouse–mouse pattern. In
conclusion, this model—the “Mouse Clone Model”—can
provide an unprecedented strategy to vigorously assess the
safety of mouse ESCs, iPSCs, and various kinds of tissue-
specific stem cells in “themselves”. Using this model in
mouse stem cell transplantation, we can, in theory, avoid
using immunodeficient mice and inbred mice to study stem
cell transplantation because of their disadvantages (Table 1).
For human stem cell therapy, because we cannot directly
test iPSCs and other stem cells in the human body, some of
the major concerns such as immune rejection and tumor
formation after transplantation cannot be determined
vigorously. With this model, we can at least investigate
whether or not the in vitro culture procedure, induction,
and differentiation might cause problems for immune
rejection and tumor formation in mice. If we can prove
experimentally that the in vitro culture, induction, andTable 1 Advantages and disadvantages of different mouse models
Mouse models Features Advan










“Mouse Clone Model” Theoretically identical with each other, and
exactly the same between transplanted
stem cells and mouse recipients
In the
and ca
normadifferentiation procedure cannot induce immune rejection
and cancer formation using this mouse model, then we
can gain more confidence that the patient-derived iPSCs
might be used for transplantation. Certainly, there are
many differences for stem cell transplantation between
mice and human, but it is worth trying. This model will
therefore lay important foundations for personalized
patient-specific tissue stem cells and iPSCs for transplant
therapy.
Another concern about stem cell transplantation therapy
is tumor formation. The discovery of cancer stem cells
(CSCs) demonstrated that, in the hierarchy of the cancer
cell population, there is a subset of stem-like tumor cells
that have the ability to self-renew and differentiate into the
diverse tumor cells [18–21]. There are good reasons to be-
lieve that during the in vitro culture of stem cells, and par-
ticularly the in vitro induction with viral integrations of
iPSCs, stem cells are exposed to risks for some mutations
and epigenetic changes [22–24]. Thus, after transplantation
into recipients, the stem cells, in some cases, can result in
various tumors [25–28]. Different immune-deficient mice
are commonly used as recipients, to facilitate the integra-
tion of transplanted stem cells. On the other hand, due to
their deficiency of immunity, some stem cells can accumu-
late to form tumors when they undergo clonal evolution
[25, 26]. Using the “Mouse Clone Model” for mouse stem
cell transplantation, theoretically—because the recipients
and stem cells and their derivatives are “selves” and have
“normal” immunity—the risks of forming tumors would be
decreased radically. This “Mouse Clone Model” could
therefore not only reduce the immune rejection radically,
but also decrease the risks of tumor formation significantly.
The advantages and disadvantages of different mouse
models are briefly presented in Table 1; for more de-
tails, refer to [29].
Ideally, the applicable iPSCs for transplantation therapy
should have full pluripotency, such as supporting full iPSC
mice. This is the gold standard for full pluripotency for
mouse ESCs and iPSCs. In addition, the iPSCs and their
differentiated stem cells should not form tumors. Com-
pared with currently used animal models for intraspecies
stem cell transplantation, the “Mouse Clone Model” is
much more advantageous for the following investigations:tages Disadvantages
different strains are available,
as C57BL/6, etc.
Not exactly the same with each other
genetically and have the potential to
induce immune reaction
different strains are available,
as nude-mice strains, etc.
Some transplanted stem cells might
result in tumors due to the weakened
immune system
ory, no immune rejection reaction,
nnot form tumor due to the
l immune system
Need tedious work and high techniques
to generate a clone of mice
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cell lines, including iPSCs and various tissue-specific stem
cells, and to select suitable stem cell lines and cloned mice
based on the immune rejection data; to investigate the
tumor formation of iPSCs and other stem cell lines and to
select suitable stem cells and cloned mice that possess low
or absent tumorigenicity based on the tumor formation
assay [27]; to investigate, after the selection of applicable
stem cells and mice, the appropriate stages of different
stem cells for their transplantation; and to genetically de-
cipher the mechanisms of immune rejection and tumor
formation more precisely. Because the stem cells and the
mouse clone are biologically “selves”, this model will
provide much stronger and direct evidence for stem
cell therapy, and further give instructions for patient-
specific iPSC-based therapy clinically. We suggest that
stem cell researchers all over the world should investigate
the applicability of iPSCs and tissue-specific stem cells for
therapeutic applications taking advantage of this model.
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